Search by category - Any -Regulated informationInside informationNon-regulated information Search by year - Any -202620252024202320222021202020192018201720162015 14 May 2021 Results of the Shareholders’ Meetings held on 14 May 2021 Regulated information 11 May 2021 Biocartis Receives EUR 1.4m Grant to Support Development of New Idylla™ Technology to Unlock Potential in Molecular Surveillance Non-regulated information 4 May 2021 Biocartis Announces New Collaboration with AstraZeneca to Expand Availability of Idylla™ EGFR Biomarker Testing Among Patients with Lung Cancer Non-regulated information 22 April 2021 BIOCARTIS Q1 2021 BUSINESS UPDATE Regulated information 22 April 2021 Biocartis and SkylineDx Sign Collaboration to Develop the Merlin Assay, a Test Predicting Risk for Nodal Metastasis in Melanoma, on Idylla™ Inside information Regulated information 20 April 2021 Biocartis Announces US FDA 510(k) submission of its Idylla™ MSI Test Non-regulated information 13 April 2021 Invitation to the Annual and Extraordinary Shareholders’ Meetings Regulated information 1 April 2021 Biocartis Announces Publication of 2020 Annual Report Regulated information 22 March 2021 Biocartis Launches Idylla™ GeneFusion Assay as Rapid Lab Workflow Solution for Gene Fusion Testing Non-regulated information 25 February 2021 BIOCARTIS ANNOUNCES 2020 RESULTS AND 2021 OUTLOOK Regulated information Pagination First page « First Previous page ‹‹ … Page 8 Page 9 Page 10 Page 11 Current page 12 Page 13 Page 14 Page 15 Page 16 … Next page ›› Last page Last »